Annexin A2: Biology and relevance to the antiphospholipid syndrome

Lupus

Volumn 17, Issue 10, 2008, Pages 943-951

  Cockrell, E ^a   Espinola, R G ^a   McCrae, Keith R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Annexin; Antiphospholipid; Endothelial; Thrombosis; 2 glycoprotein I

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOCORTIN 2; PHOSPHOLIPID ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR; BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL INTERACTION; DISEASE COURSE; DRUG RESEARCH; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMOBILIZED CELL; IMMUNOPATHOGENESIS; LIPID RAFT; MISSENSE MUTATION; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; THROMBOGENESIS; THROMBOPHILIA; VEIN THROMBOSIS; ANTIBODY COMBINING SITE; PATHOLOGY; PHYSIOLOGY; THROMBOSIS;

ANNEXIN A2; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BINDING SITES, ANTIBODY; ENDOTHELIAL CELLS; FIBRINOLYSIS; HUMANS; PHOSPHOLIPIDS; THROMBOSIS;

EID: 59649101650     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308095329     Document Type: Review

References (87)

1. Miyakis S Lockshin MD Atsumi T. et al. International consensus statement on an update of the classiciation criterial for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Giannakopoulos B Passam F Rahgozar S Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-429.
3. Rosenberg RD Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1-6.
4. Cines DB Pollak EA Buck CA. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
5. Verhamme P Hoylaerts MF. The pivotal role of the endothelium in hemostasis and thrombosis. Acta Clin Belg 2006; 61: 213-219.
6. Sagripanti A Carpi A. Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed Pharmacother 2000; 54: 107-111.
7. Zhang J McCrae KR. Annexin II mediates endothelial cell activation by antiphospholipid/anti-β2 glycoprotein antibodies. Blood 2005; 105: 1964-1969.
8. Simantov R LaSala JM Lo SK. et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
9. Del Papa N Guidala L Sala A. et al. Endothelial cells as targets for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40: 551-561.
10. Pierangeli SS Colden-Stanfield M Liu X. et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2003.
11. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 15541-15548.
12. Cesarman-Maus G Ríos-Luna N Deora AB. et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107: 4375-4382.
13. Gerke V Moss SE. Annexins: From structure to function. Physiol Rev 2002; 82: 331-371.
14. Raynal P Pollard HB. Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197: 63-93.
15. Waisman DA. Annexin II tetramer: Structure and function. Mol Cell Biochem 1995; 149/150: 301-322.
16. Hajjar KA Guevara CA Lev E Dowling K Chacko J. Interaction of the fibrinolytic receptor, Annexin, II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem 1996; 271: 21652-21659.
17. Brownstein C Falcone DJ Jacovina A Hajjar KA Annexin II. A mediator of cell surface-specific plasmin generation. Ann NY Acad Sci 2001; 947: 143-156.
18. Hayes MJ Shao D Bailly M Moss SE. Retulation of actin dynamics by annexin 2. EMBO J 2006; 25: 1816-1826.
19. Zhao W-Q Waisman DM Grimaldi M. Specific localization of the annexin II heterotetramer in brain lipid raft fractions and its changes in spatial learning. J Neurochem 2004; 90: 609-620.
20. Babiychuk EB Draeger A. Annexins in cell membrane dynamics: Ca(2+ )-regulated association of lipid microdomains. J Cell Biol 2000; 150: 1113-1124.
21. Harder T Gerke V. The annexin II(2)p11(2) complex is the major component of the TritonX-100 insoluble low-density fraction prepared from MDCK cells in the presence of Ca(2+). Biochim Biophys Acta 1994; 1223: 375-382.
22. Donato R Russo-Marie F. The annexins: Structure and function. Cell Calcium 1999; 26: 85-89.
23. Galli M Comfurius P Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1554-1559.
24. Galli M Luciani D Bertolini G Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
25. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120-4125.
26. Sheng Y Kandiah DA Krilis SA. Anti beta2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind beta2-glycoprotein I with low affinity: Dimerization of beta2-glycoprotein induces a significant increase in anti-beta2 glycoprotein I antibody affinity. J Immunol 1998; 161: 2038-2043.
27. 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheum 1995; 22: 1894-1898.
28. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid antibodies. Am J Med 1996; 101: 472-481.
29. 2-globulin des humanserums. Naturwissenschaften 1961; 48: 719-724.
30. 2 -glycoprotein-I in the rat: Isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1979; 11: 265-270.
31. Reid KBM Day AJ. Structure-function relationships of the complement components. Immunol Today 1989; 10: 177-180.
32. 2-glycoprotein I: The presence of five sushi domains. Biochemistry 1991; 30: 11687-11694.
33. 2 -glycoprotein I. Biochem J 1991; 277: 387-391.
34. 2 -glycoprotein I. FEBS Lett 1992; 313: 193-197.
35. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-659.
36. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-5174.
37. 2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-6239.
38. De Groot PG Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005; 8: 1854-1860.
39. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29-37.
40. Gharavi AE Pierangeli SS Colden-Stanfield M Liu XW Espinola RG Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol 1999; 63: 2922-2928.
41. Pierangeli SS Espinola RG Liu X Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and P-Selectin. Circ Res 2001; 88: 245-250.
42. Espinola RG Liu X Colden-Stanfield M Hall J Harris EN Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003; 1: 843-848.
43. Riboldi P Gerosa M Raschi E Testoni C Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 207: 29-36.
44. McCrae KR Feinstein DI Cines DB. Antiphospholipid antibodies and the antiphospholipid syndrome. In: RW Colman J Hirsh VJ Marder AW Clowes JN George, (eds). Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 1339-1356.
45. Dobado-Berrios PM. Lopez-Pedrera, C, Velasco, F, Cuadrado, MJ. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 2001; 44: 2467-2476.
46. Kaplanski G Cacoub P Farnarier C. et al. Increased soluble vascular adhesion molecule concentrations in patients with primary or systemic lupus erythematosus related antiphospholipid syndrome: Correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55-64.
47. Combes V Simon AC Grau GE. et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with the lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
48. Dignat-George F Camoin-Jau L Sabatier F. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673.
49. Bellagamba C Hubaishy I Bjorge JD Fitzpatrick SL Fujita DJ Waisman DM. Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding. J Biol Chem 1997; 272: 3195-3199.
50. Biener Y Feinstein R Mayak M. et al. Annexin II is a novel player in insulin signal transduction. J Biol Chem 1996; 271: 29849-29896.
51. Bevilacqua MP Pober JS Majeau GR Fiers W Cotran RS Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83: 4533-4537.
52. Anrather J Csizmadia V Brostjan C Soares MP Bach FH Winkler H. Inhibition of bovine endothelial cell activation in vitro by regulated expression of a transdominant inhibitor of NF-κB. J Clin Invest 1997; 99: 763-772.
53. Kisseleva T Song L Vorontchikhina M Feirt N Kitajewski J Schindler C. NF-kappB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 2006; 116: 2955-2963.
54. Medzhitov R Janeway C. Innate immunity. N Engl J Med 2000; 343: 338-344.
55. Dunoyer-Geindre S de Moerloose P Galve-de Rochemonteix B Reber G Kruithof EKO. NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein I antibodies. Thromb Haemost 2002; 88: 851-857.
56. Akira S. Toll-like receptor signaling. J Biol Chem 2003; 278: 38105-38108.
57. Takeda K Akira S. TLR signaling pathways. Sem Immunol 2004; 16: 3-9.
58. de Kleijn D Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60: 58-67.
59. Underhill DM. Toll-like receptors: Networking for success. Eur J Immunol 2003; 33: 1767-1775.
60. Dauphinee S Karsen A. Lipoolysaccharide signaling in endothelial cells. Lab Invest 2006; 86: 9-22.
61. Hoshino K Takeuchi O Kawai T. et al. Toll-like receptor 4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the LPS gene product. J Immunol 1999; 162: 3749-3752.
62. Raschi E Testoni D Dosisio D. et al. Role of the MyD88 transduction signaling pathway in endothelial cell activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
63. Del Papa N Sheng YH Raschi E. et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2-glycoprotein I antibodies. J Immunol 1998; 160: 5572-5578.
64. Blank M Asherson RA Cervera R Shoenfeld Y. Antiphospholipid antibody syndrome infectious origin. J Clin Immunol 2004; 24: 12-23.
65. Meroni PL Raschi E Testoni C Parisio A Borghi MO. Innate immunity in the antiphospholipid syndrome: Role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2008; 3: 510-515.
66. Pierangeli SS Vega-Ostertag ME Raschi E. et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis 2007; 66: 1327-1333.
67. Arbour NS Lorenz E Schutte BC. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191.
68. Fagerâs-Böttcher M Hmana-Aifa M Lindström A. et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114: 561-567.
69. 2GPI antibodies is mediated by annexin II cross-linking, and may involve TLR4. Blood 2004; 104: 83a.
70. 2-Glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-2697.
71. Hajjar K Jacovina AT Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-21197.
72. MacLeod TJ Kwon M Filipenko NR Waisman DA Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits. J Biol Chem 2003; 278: 25577-25584.
73. Cesarman GM Guevara CA Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
74. Hajjar KA Mauri L Jacovina AT. et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-9993.
75. Kassam G Choi KS Ghuman J. et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273: 4790-4799.
76. Kassam G Le BH Choi K-S. et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA dependent plasminogen activation. Biochemistry 1998; 37: 16958-16966.
77. Cesarman GM Guevara CA Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator. II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21195-21203.
78. Ling Q Jacovina AT Deora A. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
79. Brownstein C Deora AB Jacovina AT. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: Enhanced expression by macrophages. Blood 2004; 103: 317-324.
80. Menell JS Cesarman GM Jacovina AT McLaughlin MA Lev EA Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994-1004.
81. Ishii H Yoshida M Hiraoka M. et al. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 2001; 89: 1240-1245.
82. Lopez-Lira F Rosales LL Monroy MV Ruiz OB. The role of beta 2 glycoprotein I (beta 2 GPI) in the activation of plasminogen. Biochim Biophys Acta 2006; 1764: 815-823.
83. Yasuda S Atsumi T Ieko M. et al. Nicked beta 2 glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 3766-3772.
84. Takeuchi R Atsumi T Ieko M Ichikawa K Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti beta 2 glycoprotein I autoantibodies: Possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002; 119: 781-788.
85. McCrae KR. Annexin and APS: The clot thickens. Blood 2006; 107: 4195-4196.
86. Ieko M Ichikawa K Atsumi T. et al. Effects of beta 2 glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000; 26: 85-90.
87. van Lummel M Pennings MT Derksen RH. The binding site in {beta} 2 glycoprotein I for ApoER2" on platelets is located in domain V. J Biol Chem 2005; 280: 36729-36736.